Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
“We had some preliminary discussion with the FDA on [our AML/MDS program] and we had some really great feedback. Our recommended phase 2 dose was endorsed and we began our dose expansion. We hope to have topline data on the expansion phase internally by the end of the year... so, in the first quarter of 2022, we hope to be able to present how the expansion cohorts have done.”
Jasper Therapeutics’ JSP191 is designed to be a safer and better-tolerated conditioning regimen compared to the often-harsh regimens currently used as standard-of-care to allow stem cell therapies to successfully graft. The targeted, first-in-class humanized monoclonal antibody is designed to block stem cell signaling and activity and clear hematopoietic stem cells for donor or gene-corrected transplanted stem cell engrafting.
JSP191 is being evaluated for both myelodysplastic syndromes/acute myeloid leukemia (NCT04429191) and severe combined immunodeficiency (NCT02963064) in 2 clinical trials. The agent has so far been investigated in more than 90 healthy volunteers and patients. Jasper also recently announced a collaboration with Aruvant Sciences to study the use of JSP191 with ARU-1801, an investigational lentiviral gene therapy for the treatment of sickle cell disease.
GeneTherapyLive spoke with Kevin Heller, MD, Jasper’s executive vice president of research, about how JSP191 differs from standard-of-care conditioning regimens. He also discussed future research and data that will be presented.